AI Alliance between M3 and DEEPCORE
~ Launch of Medical A.I. Business Development Support Program ~

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/en/, “M3” below) and DEEPCORE Inc. (Headquarters: Tokyo, Japan; CEO: Katsumasa Niki; URL: http://deepcore.jp/; “DEEPCORE,” below) has announced the launch of a program that supports businesses in the medical A.I. field.

I. Background and Objective of the Alliance

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 260+ thousand physician members in Japan, offering marketing and clinical trial services. Presence outside of Japan include the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 4.5 million physicians as members across our global platforms, allows provision of services such as marketing support, marketing research, and job placement support that leverages on the platform’s powerful value as a media channel. Recent initiatives around “advanced medicine strategy” include AI Labo, established in April 2017, which currently is expanding its business by supporting development of state of the art media technologies such as diagnostic imaging and AI medical devices.

DEEPCORE is an AI specialized incubator focusing on development of young entrepreneurs in the field of deep learning. It is 100% owned by Softbank Corp. Through operations of an incubation facility, “KERNEL HONGO,” a specialized AI start-up fund, and joint venture with other corporates, DEEPCORE aims at social implementation of AI technology focused on deep learning. “KERNEL HONGO” boasts over 80 outstanding young AI engineers and researchers, and related personnel as members.
M3 and DEEPCORE will launch this new operation in effort to bring revolutionary products and services to the market through innovation of AI utility within the area of medicine. AI engineers and medical field professionals such as physicians have limited interaction, stunting the development of AI usage within the field of medicine. The two parties will hold networking events between physician AI engineers with aim to provide a solution to this hurdle and further promote clinical utility of AI technology. Innovative solutions are expected upon liaison between physicians who hold medical expertise and potential solution to issues in the field, and KERNEL members who have the ability to actualize such solutions through AI technology. Furthermore, project that lead to incorporation have potential to receive capital funding from DEEPCORE and M3.

II. M3’s Medical A.I. Development Support Offerings

M3 group will provide full support to Medical AI development.

1. Management Support Backed by Venture Investment Track Record
   i. Financial Support: Viable businesses may be eligible to receive financial support, backed by M3’s track record in venture investments (20+ investments)
   ii. Public Relations Support: Venture firms can receive PR activity support through Medical AI dedicated channels operated by M3’s AI Labo.

2. Business Development Support Through m3.com and Various Group Companies
   i. Medical Big Data Collection and Analysis Support
      Support broad collection of medical data required for AI research and development from the 260,000 Japanese and 4+ million global physician members and medical sites, to create high quality teacher data verified by multiple experts.
   ii. Clinical Research, Production and Distribution Application Support
      Regulatory strategy consulting for AI medical devices, clinical research and trial execution by M3 group’s CROs and SMOs, and rapid participant recruitment utilizing M3’s membership base all support expediting the market launch process.
   iii. Product Marketing Support
      Pre R&D marketing research service utilizing M3’s physician panel, and post market launch AI product promotion support
   iv. Global Expansion Support
      Support clinical research and licensing negotiation with global pharmaceutical companies, backed by prior business development support experience.

◆ DEEPCORE Company Overview

Name: DEEPCORE, Inc.
CEO: Katsumasa Niki
Shareholder: Softbank Corp. (100%)
URL: http://deepcore.jp/
Development of the advanced medicine business is positioned as the third growth driver for M3, following “internet based services” and “e x real operations” drivers. This initiative expands the development area of this third growth driver into the field of regenerative medicine.